MarketCapExport financials
Cyclerion Therapeutics (CYCN)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Cyclerion Therapeutics Income Statement 2026-2011 | CYCN
Brief overview of income trends at Cyclerion Therapeutics
The conclusions below are based on five years of reported results. Cyclerion Therapeutics reported revenue of 2.3 million dollars in 2020 and 2.1 million dollars by 2025. The total change was −9.7%, with a CAGR of approximately −2%. The business finished the period with a smaller revenue base.
The five-year EBITDA result moved by +93.7%: from −79 million dollars to −5 million dollars. EBITDA grew faster than revenue, indicating positive operating leverage. At the operating-margin level, the figure shifted from −3439.4% to −239.8%. Higher profitability strengthens the quality of operating growth.
Comparing the endpoints shows a move from −77.8 million dollars to −3.5 million dollars. The negative result improved without reaching break-even.
Summary assessment
The financial profile remains mixed, with strengths and risks moving in different directions. The strongest signals are net-income growth and positive operating leverage. The most visible risks are a softer top-line trend and a low EBITDA margin. Investors should continue to monitor margins, costs, and earnings quality.
Annual Income Statement Cyclerion Therapeutics
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
13 M | 9.42 M | 6.55 M | 6.78 M | 1.13 M | 41.1 M | 101 M | 93.1 M | - | - | - | - | - | - | - | - |
Shares |
4.2 M | 3.18 M | 2.52 M | 2.34 M | 2.17 M | 39.1 M | 32.1 M | 27.4 M | - | - | - | - | - | - | - | - |
Historical Prices |
3.08 | 2.96 | 2.6 | 2.9 | 0.52 | 1.05 | 3.84 | 4.28 | - | - | - | - | - | - | - | - |
Net Income |
-3.18 M | -3.53 M | -3.06 M | -5.26 M | -44.1 M | -51.6 M | -77.8 M | -123 M | -115 M | -93.9 M | - | - | - | - | - | - |
Revenue |
- | 2.07 M | 2 M | - | 297 K | 3.94 M | 2.3 M | 4.51 M | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | 2.3 M | - | - | - | - | - | - | - | - | - |
Operating Income |
-3.21 M | -4.97 M | -3.63 M | -13 M | -18.5 M | -55.2 M | -81.3 M | -125 M | -115 M | - | - | - | - | - | - | - |
EBITDA |
-3.21 M | -4.97 M | -3.63 M | -13 M | -18.5 M | -54.7 M | -79 M | -122 M | -114 M | -92.2 M | - | - | - | - | - | - |
Operating Expenses |
3.21 M | 7.05 M | 5.63 M | 2.4 M | 18.8 M | 59.1 M | 85.2 M | 130 M | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
2.48 M | 6.09 M | 5.34 M | 8.13 M | 12.9 M | 20.6 M | 28.8 M | 34.4 M | 27.5 M | 15.1 M | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Cyclerion Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
4.25 M | 4.2 M | 3.22 M | 3.07 M | 2.56 M | 2.55 M | 2.53 M | 2.51 M | 2.49 M | 2.47 M | 2.44 M | 2.28 M | 2.18 M | 2.18 M | 2.17 M | 2.17 M | 43.4 M | 43.4 M | 43.3 M | 35.7 M | 34.1 M | 34 M | 32.1 M | 27.8 M | 27.7 M | 27.6 M | 27.4 M | 27.4 M | 27.4 K | - | 27.4 K | 27.4 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-1.76 M | -3.18 M | -976 K | -324 K | -1.43 M | - | -723 K | -1.32 M | -1.54 M | - | 7.57 M | -4.18 M | -6.95 M | - | -10.5 M | -13.4 M | -13 M | - | -11.3 M | -16.2 M | -13.4 M | - | -18.8 M | -19.5 M | -20.2 M | - | -27.3 M | -32.3 M | -37.4 M | - | -29.3 M | -29.8 M | -25.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
- | - | 875 K | 93 K | 81 K | - | 194 K | - | - | - | - | - | - | - | - | 306 K | 711 K | - | 348 K | 3 M | 62 K | - | 400 K | 749 K | 1.01 M | - | 1.4 M | 1.63 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-1.77 M | -3.21 M | -1.01 M | -1.67 M | -1.46 M | - | -1.13 M | -1.38 M | -1.62 M | - | -6.02 M | -1.86 M | -3.28 M | - | -4.52 M | -13.4 M | -13 M | - | -11.3 M | -16.2 M | -13.4 M | - | -21.8 M | -19.7 M | -20.6 M | - | -28 M | -33.1 M | -37.4 M | - | -29.3 M | -29.8 M | -25.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-1.77 M | -3.21 M | - | - | - | - | - | - | - | - | - | - | - | - | -4.45 M | -13.4 M | -12.9 M | - | -10.9 M | -15.8 M | -13.1 M | - | -21.2 M | -19.1 M | -20 M | - | -27.3 M | -32.3 M | -36.9 M | - | -28.9 M | -29.4 M | -24.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
1.77 M | 3.21 M | 1.88 M | 1.76 M | 1.54 M | - | 1.32 M | 1.38 M | 1.62 M | - | 6.02 M | 2.4 M | 3.28 M | - | 4.52 M | 13.7 M | 13.7 M | - | 11.6 M | 19.2 M | 13.5 M | - | 22.2 M | 20.4 M | 21.6 M | - | 29.4 M | 34.7 M | 37.4 M | - | 29.3 M | 29.8 M | 25.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
1.77 M | 2.48 M | 1.53 M | 1.71 M | 1.5 M | - | 1.24 M | 1.28 M | 1.57 M | - | 2.13 M | 1.53 M | 2.7 M | - | 3.1 M | 3.52 M | 3.95 M | - | 4.6 M | 6.24 M | 5.36 M | - | 8.03 M | 6.63 M | 6.89 M | - | 7.12 M | 8.92 M | 11 M | - | 7.79 M | 7.53 M | 3.77 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Cyclerion Therapeutics (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Canada
Niderland
France
Israel
Australia
Schweiz
Irlanda
Danmark
